NCT02009462View on ClinicalTrials.gov

Artefill for the Treatment of HIV-associated Facial Lipoatrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
HIV-facial Lipoatrophy
Interventions
DRUG

Artefill dermal filler

Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.

Trial Locations (1)

32960

Whole Family Health Center, Vero Beach

All Listed Sponsors
collaborator

Suneva Medical, Inc.

INDUSTRY

lead

Gerald Pierone, Jr. M.D.

OTHER

NCT02009462 - Artefill for the Treatment of HIV-associated Facial Lipoatrophy | Biotech Hunter | Biotech Hunter